Literature DB >> 11908916

The role of novel antipsychotics in bipolar disorders.

Lakshmi N Yatham1.   

Abstract

Patients with bipolar disorder frequently receive antipsychotic agents during both the acute and maintenance phases of treatment. Conventional antipsychotics are effective against mania, but they may induce depressive symptoms and expose patients with bipolar disorder to increased risks of tardive dyskinesia. Recent studies have shown risperidone to be effective for acute mania, both as monotherapy and in combination with mood stabilizers; this agent has also shown efficacy as add-on maintenance therapy in open-label studies as it exhibited both antimanic and antidepressant effects. Olanzapine, another novel antipsychotic, is also effective against both manic and depressive symptoms and in the maintenance treatment as indicated by an open-label study. Data on other novel agents are more limited.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908916

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders.

Authors:  An Thyssen; An Vermeulen; Eliane Fuseau; Marc-Antoine Fabre; Erik Mannaert
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study.

Authors:  Kaan Kora; Mete Saylan; Cengiz Akkaya; Nesrin Karamustafalioglu; Nesrin Tomruk; Aziz Yasan; Timucin Oral
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Suicidal behaviour in bipolar disorder: risk and prevention.

Authors:  Leonardo Tondo; Göran Isacsson; Ross Baldessarini
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Bipolar Disorder in Neurologic Illness.

Authors:  Christopher D. Schneck
Journal:  Curr Treat Options Neurol       Date:  2002-11       Impact factor: 3.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.